Akanda Exits Cannabis, Shifts Focus Entirely to Fiber Subsidiary
AKAN sits 34% above its 52-week low of $2.295 on light trading volume (0.1× avg).
Summary
Akanda Corp. is exiting cannabis entirely, terminating its option on the BC Property and pivoting all efforts to its First Towers & Fibers subsidiary.
Key Events · M&A and Partnerships · AKAN
-
Cannabis Business Terminated
On September 24, 2026, the board determined to cease all cannabis cultivation and future cannabis-related businesses, including planned THC and CBD facilities.
-
BC Property Option Declined
The company declined the next option payment under its Amended and Restated Option to Purchase agreement with 1107385 B.C. LTD., terminating its right to acquire or use the Gabriola Island facility.
-
Strategic Pivot to Fiber
Going forward, the company will focus exclusively on growth and management of First Towers & Fibers Corp. subsidiary and potentially other business targets.
-
Nasdaq Compliance Context
This pivot follows Nasdaq's extension through December 13, 2026 to regain minimum stockholders' equity compliance, and the September 9, 2026 leadership transition to CEO Christopher Cooper.
Analysis · AKAN · Life Sciences
A fundamental strategic shift is underway at Akanda: the board has formally exited the cannabis sector, declining the next option payment on its BC Property and terminating its right to acquire or use the Gabriola Island THC/CBD facility. From here, the company will focus entirely on First Towers & Fibers Corp. This move removes a planned revenue stream and concentrates risk in the fiber subsidiary, while also coming amid Nasdaq compliance pressure and following the recent leadership transition to CEO Christopher Cooper.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1516 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKAN was trading at $3.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $2.30 to $209.03. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.